ALSO IN THIS MONTH'S ISSUE
-
Circumstances For Delaying, Denying, Limiting, Or Refusing An FDA Inspection
Delaying, denying, limiting, or refusing a drug or device inspection without a reasonable justification will result in a less than collegial atmosphere during an FDA inspection.
-
Companies To Watch: Hummingbird Bioscience
Hummingbird Bioscience is joining the forces of computational and systems biology to fight cancer and autoimmune disease.
-
Why Life Sciences Boards Need More Women
As more women rise to senior executive positions in the field, they want to have more of a leadership role. That next step is a seat on the board — and multiple boards. It’s a natural progression.
-
The Neo CEO
Lex Rovner founded her company with support from academic scientists and has headed it since it opened for business in 2018. At that time, she had no prior experience as a company founder or as a CEO.
WEB-EXCLUSIVE EDITORIAL
NEWSLETTER ARCHIVE
- 03.20.23 -- How To Improve Your CDMO Service Agreement
- 03.20.23 -- 2023 Best Practices In Decentralized Trials
- 03.17.23 -- Circumstances For Delaying/Refusing An FDA Inspection
- 03.17.23 -- Formulation Development: Improving Solubility, Compliance, And Dosing Accuracy
- 03.16.23 -- Navigating Early Drug Development To Commercial Manufacturing
LIFE SCIENCE LEADER CONTENT COLLECTIONS
ASK THE BOARD
- What New Value-Based Contracting Models For Cell And Gene Therapies Will Be Needed To Promote Broad Patient Access?
- Ongoing Economic Uncertainty And The Exit Of Generalist Investors From Biopharmaceuticals Continue To Put Pressure On Biopharma Company Leaders. What Advice Would You Offer?
- What Tips Would You Give To An Early-Stage Biopharma CEO Preparing To Present New Clinical Data At A Medical Meeting?
@LIFESCILEADER1
This website uses cookies to ensure you get the best experience on our website. Learn more